Colorectal Cancer

Tanios Bekaii-Saab, MD, FACP, discusses background that led to the start of the MOUNTAINEER-03 trial.

In an interview with Targeted Oncology, Tanios Bekaii-Saab, MD, FACP, discussed the methods and design of the MOUNTAINEER-03 trial and its role following the positive data observed from MOUNTAINEER.

Breast and gastric cancer algorithms are acceptable to use when identifying patients with colorectal cancer who may respond to tucatinib in combination with trastuzumab.

According to initial data presented at the 2023 Gastrointestinal Cancers Symposium, the novel, personalized, tumor-informed brPROPHET technology was more sensitive in detecting molecular residual disease vs other assays.

Compared with other tumor biomarkers, circulating tumor DNA may be ideal for early response assessment and have potential to enable use of adaptive clinical study designs in the future for patients with advanced colorectal cancer.

The combination use of encorafenib plus cetuximab and chemotherapy appeared to be safe and effective in treating patients with BRAF V600E-mutant metastatic colorectal cancer.

The SUNLIGHT study is the first phase 3 study in the setting of refractory metastatic colorectal cancer to demonstrate an improvement in overall survival vs an active control, according to Josep Tabernero, MD, PhD.

Tanios S. Bekaii-Saab, MD, FACP, discusses what to expect if data from the MOUNTAINEER-03 study are positive.

MOUNTAINEER study results have wowed the FDA, leading to an accelerated FDA approval of tucatinib plus trastuzumab as RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer treatment.

BXQ-350 in combination with modified FOLFOX7 and bevacizumab will be evaluated in a phase 1b/2 study of metastatic colorectal carcinoma.

Findings from the phase 2 ROCKET trial showed a benefit in progression-free survival, overall survival, and overall response rate in patients with colorectal cancer treated with RRx-001 plus irinotecan.

In an interview with Targeted Oncology, Patrick Wagner, MD, FACS, discussed the possibility of using the gut microbiome for patients with colorectal cancer, as well as his own research on the topic.

Starting with the PRESERVE 1 trial of patients with metastatic colorectal cancer, 5 pivotal trials evaluating trilaciclib will announce results in 2023.

After preclinical and early clinical studies show promising data with CTX-009 therapy, a phase 2 study of the agent has dosed its first patient with metastatic colorectal cancer.

New published findings from the phase 1/2 KRYSTAL-1 study have caught the attention for the FDA.

Real-world research show the tolerability and effectiveness of trifluridine and tipiracil combined with bevacizumab for the treatment of patients with refractory metastatic colorectal cancer.

Preclinical data shows the potential of oxMIF as a new immuno-oncology target which may be helpful in treating patients with metastatic colorectal cancers

Olumide B. Gbolahan, MBBS, MSc, discusses the key biomarkers oncologists should test for to determine the optimal treatment for patients with colorectal cancer (CRC).

A phase 1/2 study of ZN-c3, encorafenib, and cetuximab in patients with BRAF V600E-mutated colorectal cancer will begin, led by Zentalis Pharmaceuticals and Pfizer.

Investigators recommend that genomic testing be adopted to be a reflexive and natural step in evaluating patients with non–small cell lung cancer and colorectal cancer/

The use of adagrasib in combination with cetuximab or alone elicted encouraging responses in patients with advanced colorectal cancer harboring KRAS G12C mutations.

Tucatinib alone and with trastuzumab supported further investigation of each regimen in metastatic HER2-positive colorectal cancer.

At the 2022 ESMO Congress, results from the NICHE-2 trial showed neoadjuvant immunotherapy in patients with mismatch repair deficient colon cancer had notable responses to the therapy well above neoadjuvant chemotherapy.

The combination of botensilimab and balstilimab showed robust response rate, durability, and tolerability in a patients with microsatellite stable colorectal cancer.

Recent data reported from the MOUNTAINEER will support a new drug application for tucatinib in patients with metastatic colorectal cancer.